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Abstract: Multiplex Ligation-dependent Probe Amplification (MLPA) assay is a recently 
developed technique  able to evidence variations in the copy  number of several human 
genes. Due to this ability, MLPA can be used in the molecular diagnosis of several genetic 
diseases  whose  pathogenesis  is  related  to  the  presence  of  deletions  or  duplications  of 
specific genes. Moreover, MLPA assay can also be used in the molecular diagnosis of 
genetic diseases characterized by the presence of abnormal DNA methylation. Due to the 
large number of genes that can be analyzed by a single technique, MLPA assay represents 
the gold standard for molecular analysis of all pathologies derived from the presence of 
gene copy number variation. In this review, the main applications of the MLPA technique 
for the molecular diagnosis of human diseases are described. 
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1. Background 
Although the majority of human hereditary diseases are due to abnormalities in the DNA sequence 
of specific genes (point mutations), gene deletions or duplications represent a relevant portion (about 
5%) of all disease-causing mutations, and in some cases are the most frequent cause of a genetic 
disease, such as in the cases of Duchenne Muscular Dystropy (DMD) or Spinal Muscular Atrophy 
(SMA) [1–3]. The correct characterization of gene deletions and duplications is a crucial point in order 
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to identify the genotype phenotype correlation. In fact, entire and partial gene deletions/duplications 
can  produce  a  completely  different  phenotypic  effect.  A  complete  gene  duplication  can  lead  to  a 
disease due to the presence of an extra copy of the gene, while a partial duplication can lead to a loss 
of function for that gene copy, such as in the case of DMD where duplications affect some exons 
within the gene, but not the entire gene. Moreover, the complete absence of a protein or the presence of 
a partially deleted protein, lead in the first case to DMD and in the second one to BMD (see Section 3). In 
addition, it has been recently demonstrated that the genetic basis of several human diseases is related 
to  the  Copy  Number  Variation  (CNV),  generally  defined  as  a  DNA  segment,  longer  than  1  kb, 
showing  a  variable  copy  number  compared  with  a  reference  genome  [4].  At  present,  the  real 
proportion  of  genetic  diseases  caused  by  CNVs  is  unknown,  but  it  may  be  substantial,  when 
considering  that  it  has  been  suggested  that  germline  CNVs  can  also  predispose  an  individual  to 
syndromic malformations [5]. Neither conventional cytogenetic analysis or DNA sequencing is able to 
detect gene deletions/duplications and CNVs. As a consequence, these mutations must be investigated by 
using specific approaches. At the beginning, the detection of gene deletions/duplications was mainly 
based on the use of Southern Blot and FISH techniques. However, both approaches are time consuming, 
with low throughput analysis, and are not able to detect small intragenic rearrangements. On the other 
hand, CNV detection is mainly based on the use of array Comparative Genomic Hybridization (CGH), 
but results provided by  this approach must in some cases be validated  by other quantitative PCR 
methods, such as microsatellite genotyping, long-range PCR or different array CGH or genotyping 
platform [4]. 
Among the different approaches used in recent years for the detection of gene deletions/duplications 
or for the validation of array CGH results in the analysis of CNVs, particular interest has been devoted 
to the Multiplex Ligation-dependent Probe Amplification (MLPA) assay (Table 1) [6]. This technique 
is able to analyze in a single reaction up to 50 DNA sequences and to detect copy number variation of 
specific  genes,  including  small  intragenic  rearrangements.  So  far,  over  300  probe  sets  are 
commercially available from MRC Holland [6], specific for a very large range of common and rare 
genetic disorders. MLPA assay has become in a few years a widely used technique in laboratories 
performing genetic testing for the molecular diagnosis of several diseases. A search in the Pubmed 
database using the word “MLPA” displays the presence of a total of 978 scientific articles, of which 45 
in 2005, 74 in 2006, 124 in 2007, 170 in 2008, 163 in 2009, 229 in 2010, and 203 up to October 2011, 
thus demonstrating the growing interest devoted by the scientific community to this technique. In this 
review, we will describe the principles of the MLPA technique and the main applications of this assay 
in the molecular diagnosis of the most important congenital and acquired genetic diseases. Int. J. Mol. Sci. 2012, 13  3247 
 
 
Table 1. Comparison between Multiplex Ligation-dependent Probe Amplification (MLPA) 
Assay and other methods for the detection of gene deletions/duplications. 
Method  Advantages  Disadvantages 
MLPA  Detects small rearrangements 
Up to 40 targets 
High throughput 
Low cost 
Cannot detect copy neutral loss of 
heterozygosity. 
May have problems with mosaicism, tumor 
heterogeneity, or contamination with 
normal cells. 
FISH  Detects balanced 
rearrangements 
Detects mosaicism 
Detects tumor heterogeneity 
Can quantify multiple copies 
Cannot detect copy neutral loss of 
heterozygosity. 
Cannot detect small rearrangements  
(e.g., deletions <100 kb or 
duplications >500 kb). 
Limited number of targets and throughput. 
Quantitative/Sq-PCR  Detects small rearrangements 
and even point mutations 
Can quantify multiple copies 
Low cost 
Test optimization and efficiency is a 
concern. 
Limited number of targets. 
May have problems with mosaicism, tumor 
heterogeneity, or contamination with 
normal cells. 
Southern blot  Detects small rearrangements 
Detects mosaicism 
Cannot detect copy neutral loss of 
heterozygosity. 
Not quantitative. 
Laborious and time consuming 
Limited number of targets and throughput. 
CGH array  Can detect very small 
rearrangements 
Can probe entire genome 
Low cost per data point 
Cannot detect copy neutral loss of 
heterozygosity. 
Costly equipment and reagents 
Low throughput 
SNP array  Can detect copy neutral loss or 
heterozygosity 
Can probe entire genome 
Low cost per data point 
Cannot detect small rearrangements  
(e.g., deletions or duplications <100 kb). 
Costly equipment and reagents 
Low throughput 
2. Principles of MLPA Assay 
MLPA is a multiplex PCR assay that utilizes up to 40 probes, each specific for a different DNA 
sequence (mainly exons of a specific gene of interest), to evaluate the relative copy number of each 
DNA sequence. Each probe is composed of two half-probes (5' and 3' half-probes), consisting of a 
target-specific sequence and a universal primer sequence allowing the simultaneous multiplex PCR 
amplification of all probes [6]. In addition, one or both half-probes contain a stuffer sequence allowing 
differentiation during electrophoresis of the length of the probe itself, and, as a consequence, the size 
of the amplification product. The MLPA reaction can be divided into five steps: (1) DNA denaturation 
and probes hybridization; (2) ligation reaction; (3) PCR amplification; (4) separation of amplification 
products by electrophoresis; (5) data analysis. In the first step, the DNA is denatured and incubated Int. J. Mol. Sci. 2012, 13  3248 
 
 
with a mixture of MLPA probes. The two half probes are able to recognize contiguous target-specific 
sequences, and only in the presence of a perfect match without a single gap, after hybridization, can 
the two half-probes be ligated and amplified. PCR amplification is performed using only one PCR 
primers pair, one of which is fluorescently labelled. Because only ligated probes will be amplified 
during the subsequent PCR reaction, the number of probe ligation products is a measure of the number 
of  target  sequences  in  the  sample.  PCR  products  are  then  separated  by  size  using  Capillary 
Electrophoresis  under  denaturing  conditions.  The  height  or  area  of  the  PCR  derived  fluorescence  
peaks is measured, quantifying the amount of PCR product after normalization and comparing it with 
control DNA samples, thus indicating the relative amount of target DNA sequence in the input DNA 
sample  [6,7].  The  quality  of  the  reaction  is  assessed  by  the  presence  of  control  peaks  providing 
information about the efficiency of the amplification and the correct amount of DNA used for the 
reaction. A key point in the MLPA reaction is that PCR does not amplify the target sequences, but the 
ligated probes. Thus, a single pair of PCR primers is used for the amplification, while typical multiplex 
PCR requires the use of specific PCR primers for each target sequence. 
A crucial point in the use of MLPA assay as a genetic test for the molecular diagnosis of gene 
deletions/duplications is the interpretation of the MLPA results. Homozygous or hemizygous deletions 
are clearly evidenced by the absence of the specific peaks for the target gene, in the presence of a 
normal amplification of control probes. On the other hand, heterozygous deletions, duplications and 
CNVs produce a different height and/or area of the relative peaks, and the interpretation of these 
results can be challenged by the presence of different efficiencies of the PCR reaction among the 
different probes and sample-to-sample variations. As a consequence, different MLPA data analysis 
strategies have been developed to allow a correct interpretation of the reaction raw data. Among these, 
the most widely used is the Coffalyser software, an Excel-based program able to perform all data 
normalization  steps  and  corrections  for  signal  sloping  Also  other  software  have  been  recently  
released [8–10]. 
3. MLPA Applications in Genetic Testing 
3.1. MLPA and Neuromuscular Disorders 
Several types of inherited neuromuscular disorder are due to deletions or duplications of specific 
genes. Among these, Dystrophinopaties (Duchenne Muscular Dystrophy, DMD, and Becker Muscular 
Dystrophy,  BMD),  Spinal  Muscular  Atrophy  (SMA),  Charcot  Marie  Thoot  (CMT)  disease  and 
Hereditary  Neuropathy  with  liability  to  Pressure  Palsies  (HNPP)  represent  a  large  portion  of  all 
mendelian  neuromuscular  disease  for  which  genetic  testing  is  routinely  carried  out  for  diagnostic 
purposes, for the identification of healthy carriers and for the evaluation of the recurrence risk. For this 
reason, MLPA assay represents a powerful tool for the study of these different conditions. 
 
3.1.1. Dystrophinopathies 
DMD and BMD are X-linked diseases affecting 1:3500 and 1:18,000 birth males, respectively, both 
caused by mutations of the DMD gene on Xp21.2. In about 65% of DMD cases and up to 85% of BMD 
cases the pathogenic mutation is represented by large deletions of the DMD gene, while duplications of Int. J. Mol. Sci. 2012, 13  3249 
 
 
the same gene account for 5–10% of cases and point mutation are responsible for the remaining 25–30% 
of cases [2,11–14]. In affected males, about 98% of deletions are easily detectable using a multiplex  
PCR approach, able to analyze two hot spot regions (exons 2–20 and 44–53) [2,15,16]. However, this 
approach is not able to detect heterozygous deletions in female carriers, which represents a crucial 
point for the calculation of the recurrence risk of the disease within a family and the prevention of  
the birth of affected children. In fact, about one third of DMD cases are due to “de novo” mutations in 
children whose mothers are not healthy carriers and are thus at very low risk of recurrence of the 
disease. Moreover, DMD gene duplications cannot be detected by multiplex PCR approach either in 
affected males or in female carriers. As a consequence, a number of different approaches has been 
suggested  for  the  identification  of  DMD  duplications  and  heterozygous  deletions,  such  as  linkage 
analysis  [17,18],  quantitative  analysis  of  gene  dosage  [19,20],  FISH  analysis [21,22],  Entangled 
Solution Capillary  Electrophoresis  (ESCE)  [23],  Primed  In  Situ  Labeling  (PRINS)  combined  with 
FISH [24], Multiplex Amplifiable Probe Hybridisation (MAPH) [25], quantitative real time PCR [26] 
and CGH array [27,28]. MLPA analysis, based on the use of two SALSA kits able to investigate all  
the exons of the DMD gene and several control probes on sex chromosomes and autosomes, have  
been used by several groups in the study of DMD and BMD, both in affected patients and in female 
carriers [29–35]. All these studies reported MLPA as a simple, rapid and reliable tool in the screening 
of deletions and duplications of the DMD gene, based on its ability to simultaneously hybridize and 
amplify all of the 79 DMD exons in only two reactions tubes, allowing a reduction in labor intensity 
compared with ESCE, PRINS, real-time PCR and MAPH. The usefulness of MLPA assay is evident in 
the study of suspected carrier females, where this approach represents a first choice method for the 
detection of heterozygous deletions/duplications and thus for the assessment of the carrier status in 
female relatives of affected males (Figure 1). 
In the study of affected patients, the MLPA ability to analyze all of the DMD exons provides high 
sensitivity and specificity and a sharp identification of the breakpoints of the rearrangements. This 
latter represents a crucial point in the management of DMD affected patients, since the determination  
of  the  full  extent  of  the  DMD  gene  deletions/duplications  is  critical  knowledge  for  possible  gene 
therapy strategies based on the skipping of specific exons involved in the deletion [32]. However, 
although some authors suggested that the identification of all exons involved in the deletion is critical 
for predicting the progression of the disease [32], it must be stressed that MLPA analysis is not able to 
provide information about the “in frame” or “out of frame” status of the deletions, which represents the 
crucial difference between DMD and BMD causing mutations. The frame-shift mutations in DMD 
patients result in the complete absence of dystrophin in their skeletal muscle because the translational 
reading frame of the mRNA is not maintained, whereas muscle tissue from BMD patients contains 
truncated dystrophin translated from the in-frame mRNA. The difference between “in frame” or “out of 
frame” deletions can be due to the involvement of even a single nucleotide, and is thus not detectable by 
MLPA, able to evidence the involved exons but not to identify the specific break points of the deletion. 
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Figure  1.  Multiplex  Ligation-dependent  Probe  Amplification  (MLPA)  analysis  of  the 
Duchenne Muscular Dystrophy (DMD) gene. Abscissa represents DMD gene and control 
probes (c); ordinate represents fluorescent intensity of amplification. For each probe, the 
ratio <0.75 stands for deletion; and the ratio >1.3 stands for duplication. (a) MLPA analysis 
showing a heterozygous deletion of exons 46–50 (ratio < 0.75) of the DMD gene in the 
mother of an affected patient; (b) Normal control (075 < ratio < 1.3). 
 
(a) 
 
(b) 
A crucial point in the interpretation of MLPA results is represented by the detection of deletions 
involving a single DMD exon. In these cases, in fact, the apparent deletion could actually consist of a 
change in the exon sequence hampering the correct hybridization of the specific probe. This sequence 
variation can be represented either by a DMD pathogenic point mutation or by a polymorphism not Int. J. Mol. Sci. 2012, 13  3251 
 
 
affecting gene function. Thus, apparent single exon deletions detected by MLPA should be checked by 
an independent method [31]. 
In order to further improve the throughput and speed of the MLPA approach in the diagnosis of  
DMD gene rearrangements, a modification of the original protocol has been described involving the 
use of a 96-well flow-through microarray system for the detection of the different probes, allowing the 
hybridization to be completed in 5 to 30 min [36]. In addition, a possible improvement in the detection 
rate of MLPA analysis is represented by the use of probe multiplexes, including specific probes for 
common  point  mutations  of  the  DMD  gene,  allowing  both  full  dosage  analysis  and  partial  point 
mutation analysis in a single test [37]. 
3.1.2. SMA 
SMA (classified in SMA I, II and III according to the severity of symptoms) is a neuromuscular 
disease characterized by symmetric proximal muscle weakness due to degeneration of the anterior 
horn cells of the spinal cord. SMA is inherited as an autosomal recessive trait with a prevalence  
of about 1 in 10,000 newborns and a carrier frequency of 1 in 50 [38]. All the three SMA types are 
caused by homozygous mutations of the survival motor neuron 1 (SMN1) gene (5q13), which in about 
95% of cases is represented by the functional absence of this gene due to deletion or its conversion to 
SMN2. This latter gene, mapped within the SMA critical region, is not directly related to the disease, 
but is considered a disease-modifying gene because its copy number relates to the disease severity and 
survival of affected patients [39–42]. 
The standard molecular diagnosis of SMA is based on a PCR-RFLP test, able to detect homozygous 
SMN1 loss [43]. However, this method does not detect heterozygous SMN1 loss, and cannot be used 
for identifying healthy carriers, which can be checked by linkage or quantitative analysis of SMN1 
copy number. As in the case of the DMD gene, also in the case of SMA several additional techniques 
have been proposed for the identification of healthy carriers, including LightCycler PCR [40], TaqMan 
Technology [44], and denaturing high-performance liquid chromatography [45]. 
MLPA assay for the molecular diagnosis of SMA is based on a kit containing several probes for the 
SMA critical region, including specific probes for SMN1 and SMN2 genes, probes able to hybridize both 
genes and other probes for sequences mapped either within the SMA critical region (NAIP, GTF2H2,  
N-cadherin-like, CDH6 and RAD17 genes) or on other autosomal regions. Due to this specific probe set, 
MLPA assay for the SMA critical region is able to detect the copy number of both SMN1 and SMN2 
genes. As a consequence, both homozygous and heterozygous SMN1 deletions or conversions to SMN2, 
can be detected, allowing the diagnosis of affected patients or healthy carriers. Moreover, the assessment 
of SMN2 copy  number  can provide useful information in order to evaluate the  genotype-phenotype 
correlation. Different groups have investigated the efficiency of MLPA in the molecular diagnosis of 
SMA, both in affected patients and in healthy controls [46–51]. Based on the obtained results, MLPA 
analysis can be considered as the gold standard technique in the molecular diagnosis of SMA, providing 
an easy, fast, and high throughput system for analyzing the SMA critical region both in affected patients 
and in healthy carriers. The advantages of MLPA assay have been particularly stressed in a study  
of Arkblad et al., showing that this technique allowed the identification of a previously unreported, 
partial deletion of SMN1 in two apparently unrelated Swedish families, which would not have been Int. J. Mol. Sci. 2012, 13  3252 
 
 
detected by conventional diagnostic methods [47]. Due to its ability to simultaneously analyze several 
samples,  MLPA  analysis  can  be  used  for  population  screening  of  SMA  healthy  carriers  in  specific 
conditions, such as in a couple undergoing Assisted Reproduction Techniques. In this light, very recently 
the usefulness of SMN1 genotyping in carrier screening for SMA has been suggested by the American 
College  of  Medical  Genetics,  and  MLPA  approach  has  been  used  in  this  context  [52].  The 
simultaneous analysis of different sequences within and outside the SMA critical region provides an 
accurate control system, reducing the risk of false positive and false negative results. Moreover, a 
quick MLPA-based assay for the detection of SMN1 and SMN2 copy numbers with high specificity 
and low complexity has been recently developed [53]. On the other hand, MLPA assay is not able 
either to detect SMN1 point mutations or to disclose the presence of two SMN1 copies in the same 
allele. However, these conditions account for less than 5% of SMA cases. 
3.1.3. CMT and HNPP 
Charcot-Marie-Tooth disease (CMT) is the most common inherited peripheral neuropathy. Among 
the  different  CMT  forms,  CMT1  is  characterized  by  the  presence  of  demyelinating  neuropathies  
with  severe  reduction  in  the  motor  nerve  conduction  velocities.  CMT1A  is  the  most  common  
type, representing about 70 to 80% of all CMT, and is transmitted as an autosomal dominant trait. The 
majority of CMT1A cases are caused by a tandem duplication of a 1.5-Mb region encompassing the 
PMP22 gene on 17p11.2-p12 [54]. Deletions involving the same gene cause a distinct genetic disease, 
namely  Hereditary  Neuropathy  with  Liability  to  Pressure  Palsies  (HNPP)  [55].  The  incidences  
of each CMT1A and HNPP are estimated to be as high as 1 in every 2500 individuals [56]. The 
usefulness of MLPA assay in the detection of PMP22 duplications and deletions for the molecular 
diagnosis of CMT1A and HNPP, respectively, has been investigated by Slater et al. in a study carried 
out by comparing the performance of this technique with one of interphase FISH analysis. Authors 
evidenced a very high concordance of FISH and MLPA, since only one of 50 paired tests produced a 
false result with FISH analysis, and concluded that MLPA assay represents a robust, simple, and cost-
effective approach for the molecular diagnosis of CMT1A and HNPP [57]. Thus, this technique is now 
currently  used  for  the  molecular  diagnosis  of  PMP22  duplications  (Figure  2).  Moreover,  MLPA 
analysis has been recently used in studies aimed at the identification of alterations of the 17p12 region 
not involving the PMP22 gene [58,59]. 
3.2. MLPA and Analysis of the SHOX Gene 
The  Short  Stature  Homeobox  containing  gene  (SHOX),  mapped  within  the  Pseudoautosomal 
Region  1  (PAR  1)  of  the  X  and  Y  chromosomes,  is  involved  in  the  regulation  of  growth  and  is  
related to different diseases such as Turner syndrome (TS), Idiopathic Short Stature (ISS), Leri Weill 
dyschondrosteosis (LWD) and Langer disease (LS) [60]. The majority of mutations causing SHOX 
deficit is represented by deletions within the coding region of this gene or involving a region mapped 
several hundred kilobases downstream of the coding region and containing conserved non-coding DNA 
elements (CNE) acting as regulatory elements (enhancer) of SHOX [61–64]. SHOX mutations affect one 
to  two  in  1000  individuals,  representing  the  most  common  mendelian  disease  in  the  Caucasian 
population [65].  Due  to  the  high  frequency  of  alterations  of  the  SHOX  gene  and  to  the  recently Int. J. Mol. Sci. 2012, 13  3253 
 
 
demonstrated good response to the treatment with growth hormone (GH) in patients with short stature 
due to SHOX deficiency, the early identification of SHOX alterations has become crucial not only for 
the diagnosis of the pathogenesis of the disease, but also for the therapeutic strategy [66–67]. The main 
approaches originally used for the detection of SHOX deletions were FISH or microsatellite analysis, 
which  are  both  low  throughput,  time  consuming  analyses,  not  useful  for  application  in  a  screening 
program, and also considering that short stature is a very common condition affecting about 3% of the 
population. The usefulness of the MLPA approach in the study of the SHOX gene has been tested by 
different groups, and it has been demonstrated that this approach represents the gold standard for the 
detection of the SHOX gene alterations [64,68–72]. In fact, MLPA is able to detect different SHOX 
gene rearrangements (including small intragenic deletions not detectable by FISH analysis) to evidence 
the breakpoints of the deletion and to disclose the presence of complex rearrangements involving other 
genes mapped on the X and Y chromosomes [68]. Moreover, the MLPA probes set for the study of the 
SHOX gene include several probes specific for the SHOX enhancer region, being thus able to detect also 
rearrangements of this regulatory region. Finally, very recently MLPA analyses have also demonstrated 
that SHOX gene duplications can be responsible for the SHOX deficit [72]. MLPA analysis is not able to 
detect point mutations, but these account for a minor portion of SHOX gene alterations and are generally 
investigated only in second level analysis when the presence of deletions of the coding region or of the 
enhancer region have been ruled out. 
Figure  2.  MLPA  analysis  of  the  PMP22  gene.  Abscissa  represents  PMP22  gene  and 
control probes (c); ordinate represents fluorescent intensity of amplification. For each probe, 
the ratio <0.75 stands for deletion; and the ratio >1.3 stands for duplication. (a) duplication 
of the PMP22 gene (ratio > 1.3) in a patients affected by Charcot Marie Thoot (CMT) 
disease; (b) Normal control (075 < ratio < 1.3). 
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3.3. MLPA in Prenatal Diagnosis 
Prenatal diagnosis, based on the withdrawal and culture of chorionic villi (CV) or amniotic fluid 
(AF) samples during pregnancy followed by chromosome investigation, is a largely used assay for the 
detection of genetic alteration of the fetus. However, two main limits of this approach are represented 
by  the  risk  of  abortion  related  to  the  villocentesis  or  amniocentesis  procedures,  and  the  waiting  
time required for the culture and analysis of samples. Different methods based on the screening of the 
mist common aneuploidies on uncultured chorionic villi or amniocytes, such as FISH or QF-PCR, are 
currently used to provide a first result within 24–48 h, followed up by conventional karyotyping on 
cultured cells. In recent years, the use of MLPA for the screening of aneuplodies of 13, 18, 21, X and 
Y chromosomes has been suggested. Slater et al. assessed the performance of MLPA analysis for rapid, 
high throughput prenatal detection of common aneuploidies in a blind, prospective trial conducted on 
492 amniotic samples [73]. Authors evidenced no failed tests and the clear identification of all autosomal 
aneuploid cases. Sex determination was also 100% accurate. Based on these results, authors suggested 
that MLPA is a rapid, flexible, sensitive, and robust test for prenatal aneuploidy detection. Gerdes et al. 
reported a study on 1593 samples (809 AF and 784 CV) in which prenatal diagnosis was performed by 
using both conventional cytogenetic investigation and MLPA assay [74]. For the purposes of the study, 
MLPA analysis was organized for completion and reply within 2 days from receipt of the sample. 
Authors  evidenced  no  incorrect  MLPA  results,  but  51  out  of  1593  MLPA  analyses  (3.2%)  were 
defined as “inconclusive”. van Opstal et al. reported a large prospective study on 4000 AF samples 
using MLPA in order to detect aneuploidies of 13, 18, 21, X and Y chromosomes, obtaining 3932 
conclusive (98.3%) and 68 (1.7%) inconclusive results [75]. Among conclusive results, in 76 cases 
(1.9%) there resulted a normal MLPA analysis, karyotype investigations disclosed the presence of 
abnormalities  such  as  structural  chromosome  aberrations,  69,XXX  karyotpye,  
sex-chromosomal  mosaicisms,  mosaic  aneuploidies  different  from  the  investigated  ones  and Int. J. Mol. Sci. 2012, 13  3255 
 
 
mosaicism of an extra marker chromosome. All these kinds of aberrations were not expected to be 
detected by MLPA analysis. The inconclusive results were due to the presence of blood contamination 
of the AF sample, an insufficient amount of DNA or to unknown reasons. Guo et al. developed a 
MLPA/rtPCR approach to simultaneously detect trisomies 21, 18 and 13 in a single reaction, and 
investigated 144 blinded clinical samples including 32 cases of trisomy 21, 11 cases of trisomy 18, one 
case of trisomy 13, and 100 unaffected control samples, comparing results with karyotype analysis. 
MLPA/rtPCR correctly detected all cases of trisomy even when present in mosaic, suggesting that this 
approach may have applicability in noninvasive prenatal diagnosis with maternal blood samples [76]. 
Very  recently,  Yan  et  al.  developed  a  method  of  array-based  MLPA  containing  116  universal  
tag-probes covering chromosomes 13, 18, 21, X, and Y, and 8 control autosomal genes to rapidly 
screen  for  common  aneuploidies.  In  a  blind  study  of  161  peripheral  blood  and  12  amniotic  fluid 
samples  previously  karyotyped,  these  authors  evidenced  that  97.7%  of  samples,  including  all  the 
amniotic fluid samples, were correctly identified by array-MLPA. Authors evidenced the successful 
application and strong potential of array-MLPA in clinical diagnosis and prenatal testing for rapid and 
sensitive  chromosomal  aneuploidy  screening  [77].  Thus,  MLPA  analysis  appears  to  be  a  good 
candidate to replace interphase FISH analysis for the screening of the most common chromosomal 
aneuplodies,  although  the  karyotype  investigation  still  remains  the  gold  standard  for  a  complete 
prenatal diagnosis. 
3.4. MLPA and Cancer 
Several  studies  have  investigated  the  usefulness  of  MLPA  analysis  in  the  molecular  study  of 
different forms of cancer. The three main applications of MLPA assay in this field are (i) analysis of 
germ  line  deletions/duplications  in  genes  related  to  hereditary  cancers;  (ii)  analysis  of  somatic 
deletions/duplications  in  genes  involved  in  the  progression  of  the  disease  and  to  the  response  to 
therapy; (iii) analysis of DNA methylation as a mechanism of inactivation of tumor suppressor genes. 
This last topic will be discussed in a specific paragraph. 
3.4.1. MLPA and Hereditary Cancers 
Hereditary  cancers  are  those  in  which  the  presence  of  a  germline  mutation  causes  a  hereditary 
predisposition to the disease. Among these, the most common types are represented by Breast Cancer 
(BC) and Ovarian Cancer (OC) due to mutations of the BRCA1 and BRCA2 genes, Familial adenomatous 
polyposis (FAP) due to mutations of the APC gene, and Hereditary Nonpolyposis Colorectal Cancer 
(HNPCC) due to mutations of the genes involved in the mismatch repair. The identification of mutations 
of the above mentioned genes in patients affected by hereditary cancer and in their relatives is of crucial 
importance  in  order  to  set  up  specific  prophylactic  strategies.  In  the  majority  of  cases,  germ  line 
mutations affecting these genes are represented by point mutations; however, in the last year, a number 
of studies have demonstrated that gene deletions/duplications are detectable in a portion of cases which 
are negative to the screening of point mutations. Several techniques have been used by different groups 
for  the  identification  of  these  rearrangements,  including  MLPA  [78].  Several  groups  have 
demonstrated the usefulness of MLPA assay in the analysis of genomic rearrangements of BRCA1  
and  BRCA2.  Hogervorst  et  al.  using  MLPA  evidenced  the  presence  of  five  distinct  BRCA1 Int. J. Mol. Sci. 2012, 13  3256 
 
 
deletions/duplications  in  a  series  of  661  families  with  BC  in  which  the  screening  of  BRCA1  and 
BRCA2 point mutations was negative, suggesting that large genomic rearrangements could account for 
a large portion (about 27%) of all the BRCA1 mutations in families with hereditary BC [79]. These 
data were confirmed by Montagna et al., who reported that genomic rearrangements account for more 
than one-third of the BRCA1 mutations in northern Italian breast/ovarian cancer families as evidenced 
by MLPA analysis [80]. Subsequently, several other studies corroborated the high frequency of BRCA1 
deletions/duplications in families with hereditary BC/OC, although with variable prevalence [81,82]. 
Other studies have demonstrated  that  the  detection  rate  of  BRCA1  and  BRCA2  rearrangements  by 
MLPA increases in selected families, such as in the study reported by Woodward et al., who evidenced 
a high frequency of deletions/duplications in multiple case breast/ovarian families with a young age of 
onset  (BRCA1)  and  in  families  containing  at  least  one  case  of  male  breast  cancer  (BRCA2)  [83].  
In this view, Veschi et al. evidenced a very high carrier detection rate of mutation screening plus 
MLPA analysis in patients in which a high risk to be a carrier had been assessed by the BRCAPro 
software [84]. Taken together, all these studies strongly suggest the usefulness of MLPA analysis for 
the search of deletions/duplications of BRCA1 and BRCA2 genes in patients without point mutations of 
these genes. 
The  application  of  MLPA  analysis  has  provided  useful  results  also  in  the  study  of  large 
rearrangements of the APC gene in patients affected by FAP and their relatives. Bunyan et al. detected 
complete or partial gene deletions of APC in six cases out of 24 patients with FAP (25% of mutation 
negative  FAP;  8%  of  all  FAP)  [85].  Michils  et  al.,  using  different  techniques,  including  MLPA, 
evidenced APC deletions in 15% of mutation-negative patients with classical FAP, but not in the 
attenuated  FAP  [86].  In  other  studies,  MLPA  analysis  allowed  the  detection  of  rearrangements 
different from deletions as pathogenic mutations of AFP in FAP, such as duplications or complex 
rearrangements  [87,88].  MLPA  assay  has  been  also  successfully  used  for  the  deletions  of  large 
rearrangements of genes of the mismatch repair in HNPCC. Nagakawa et al., in a series of 70 individuals 
at  risk  for  Lynch  Syndrome,  found  6  deletion  cases  by  MLPA  assay  which  were  confirmed  and 
characterized by other techniques [89]. Taylor et al. analyzed by MLPA 215 UK patients referred for 
genetic testing on the basis of a family history consistent with autosomal dominant hereditary HNPCC 
and  found  12  cases  with  deletions  of  one  or  more  exons  (six  involving  MLH1  and  six  MSH2), 
providing  evidence  that  the  overall  mutation  detection  sensitivity  in  their  series  was  increased  by 
approximately  50%  by  the  inclusion  of  MLPA,  for  an  additional  testing  cost  of  about  10%  [90].  
Wang et al. investigated 112 patients for large deletions of MLH1 and MSH2 by MLPA, detecting 
deletions  in  19  patients  (11  in  MSH2  and  eight  in  MLH1,  respectively)  [91].  All  these  authors 
concluded that large genomic deletions in both MSH2 and MLH1 genes play a considerable role in the 
pathogenesis of HNPCC and should be part of the routine mutation detection protocols. These data 
were confirmed by several other reports, and MLPA analysis is now considered as a routine approach 
in the study of the genetic basis of hereditary HNPCC [85,92–95]. However, also in this case it has 
been suggested that some apparent deletions of single exons may actually result from single base 
substitutions or small insertions/deletions in the hybridisation sequence of MLPA probes, and that 
these alterations should be validated with additional methods [96]. 
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3.4.2. MLPA and Somatic Mutations in Cancer 
A  wide  range  of  MLPA  probe  mixes  for  the  molecular  characterization  of  cancer  samples  are 
available, mostly aimed at the identification of somatic deletions/duplications in genes involved in the 
progression of the disease and to the response to therapy. An important advantage in the use of the 
MLPA  assay  in  this  field  is  provided  by  the  ability  of  this  technique  to  work  on  formalin-fixed 
paraffin-embedded  tissue,  as  demonstrated  by  van  Dijk  et  al.  by  analyzing  DNA  isolated  from 
formalin-fixed  melanomas  previously  characterized  by  CGH.  These  authors  reported  that  MLPA 
resulted as a reliable and efficient method to evaluate DNA copy number changes as 86% of the tested 
loci  revealed  concordant  CGH  results,  and  the  discordance  mainly  involved  alterations  that  were 
detected by MLPA but not by CGH, likely due to the lower resolution of this latter technique and/or to 
occasionally false positive MLPA results [97]. Thus, MLPA assay has been largely used in retrospective 
studies on large series of cancer samples based on the use of paraffin embedded tissues. Due to the large 
number of reports describing the usefulness of MLPA assay in this field, only a few studies have been 
selected in this review as examples of different applications. In several studies, MLPA assay has been 
used for the detection of gene deletions/duplications during the progression of several cancer types, in 
order to relate the detected aberrations with the progression of the disease. Jeuken et al. performed 
MLPA analysis to detect relevant genetic markers in a spectrum of 88 gliomas, the majority of which 
were previously characterized by CGH assay. MLPA analysis was able to detect complete and partial 
loss of 1p and 19q even in samples containing only 50% tumor DNA. Moreover, this assay was able to 
identify distinct 1p deletions showing different clinically prognostic consequences, in contrast to the 
commonly used diagnostic strategies such as loss of heterozygosity or FISH. Authors evidenced that 
the  combined  use  of  two  MLPA  probe  mixes  allows  the  identification  of  markers  of  high-grade 
malignancy such as EGFR, PTEN, and CDKN2A in 41 cases analyzed, further increasing the accurate 
prediction  of  clinical  behavior  [98].  Franco  Hernandez  et  al.  analyzed  by  MLPA  and  real-time 
quantitative PCR gene-dosage of the EGFR gene 41 oligodendroglial tumors, evidencing the presence 
of an overdose (one- to five-fold increase) in 21 samples (52.5% of cases) [99]. MLPA assay has been 
used also for the study of genomic profiles of ovarian and fallopian tube carcinomas, and it has been 
suggested that dedicated MLPA sets constitute potentially important tools for differential diagnosis and 
may provide footholds for tailored therapy for these tumors [100]. Subsequently, the study of genomic 
profiles by MLPA has been extended to several tumors, such as Multiple Endocrine Neoplasia type I, 
neuroblastoma,  meningiomas,  larynx  and  pharynx  carcinomas,  melanoma,  oligodendrogliomas  and 
glioblastomas, gastric cancers, lung cancer, renal carcinoma and others [101–112]. 
MLPA  assay  has  been  used  also  for  investigations  of  gene  deletion/duplication  in  leukemias.  
Buijs et al. performed genomic profiling using MLPA in 54 cases with suspected or advanced chronic 
lymphocytic leukemia (CLL), showing that MLPA is able to detect anomalies when the percentage of 
mutated cells was greater than 35% [113]. A similar study was carried out by Coll-Mulet et al., who 
performed MLPA in 50 CLL patients to identify multiple genomic CLL-specific targets, comparing 
the results with those obtained with FISH. Authors evidenced a good correlation between MLPA and 
FISH results, as most alterations (89%) were detected by both techniques. Only cases with a low 
percentage (<25%) of cells carrying the alterations were not detected by MLPA, but this technique was 
able to identify intragenic or small alterations undetected by FISH. Authors concluded that the major Int. J. Mol. Sci. 2012, 13  3258 
 
 
advantage of the MLPA assay is the ability to provide a simultaneous analysis of many samples with 
automated data processing at a low cost [114]. The usefulness of MLPA assay in the study of CLL has 
been  further  demonstrated  by  other  studies  [115–118],  and  more  recently  acute  leukemias  and 
mielodysplastic  syndromes  have  also  been  analyzed,  again  disclosing  excellent  accuracy  and 
specificity of MLPA as compared to FISH and providing a clinically robust, high-throughput, high-
resolution option for detection of abnormalities associated with these diseases [119,120]. 
In other cases, MLPA assay has been used for the detection of gene deletions/duplications related  
to the response to therapy of specific cancers. In this respect, the MLPA assay has been used for the 
determination  of  the  status  of  the  HER-2/neu  transmembrane  tyrosine  kinase  receptor,  which 
represents  a  prognostic  marker  and  a  therapeutic  target  for  breast  cancer,  being  considered  a 
prerequisite for selecting breast tumors for immunotherapy or for taxan based chemotherapy [121]. 
MLPA results obtained on a group of 60 breast cancer patients were compared with those provided by 
immunohistochemistry  (IHC),  showing  a  good  correlation  between  HER-2/neu  gene  amplification 
detected  by  MLPA  and  overexpression  by  IHC  in  invasive  breast  cancer.  Authors  concluded  that 
MLPA  is  an  attractive  method  for  detecting  HER-2/neu  amplification  in  daily  laboratory  
practice [121]. A similar study was carried out by Moerland et al., who evaluated the detection of 
HER2 gene amplification using MLPA in comparison with FISH on a series of 46 formalin fixed 
paraffin embedded breast carcinomas, previously tested for protein overexpression by HercepTest. All 
but  one  FISH  positive  cases  (18/19)  were  confirmed  by  MLPA  for  the  presence  of  the  gene 
amplification, with a 98% overall concordance of detection of Her2 gene amplification by FISH and 
MLPA. Also in this case, authors concluded that MLPA is a reliable and reproducible technique that 
can be used either as an alternative or additional test to determine HER2 status in breast carcinomas [122]. 
These results were confirmed on a larger series by the same group, who compared MLPA, FISH and 
chromogenic in situ hybridization (CISH) in the assessment of the HER-2/neu gene amplification status 
with protein overexpression by IHC in 518 breast carcinoma patients. Authors evidenced that about 10% 
of their cases overexpressed HER-2/neu at the protein level (IHC), and 11% of cases showed gene-
amplification by MLPA. A high concordance was found between FISH and CISH, MLPA and IHC, and 
MLPA and CISH, confirming that MLPA is a fast, accurate and cheap method to detect breast cancer 
HER-2/neu amplification in small quantities of DNA extracted from paraffin blocks, and thereby a 
reliable alternative to FISH and CISH [123]. The same authors also demonstrated an increase in the 
concordance between MLPA and ISH from 61% to 84% after manual microdissection of the tumor 
sample and to 90% after laser microdissection, suggesting that microdissection before MLPA may be 
advisable in the case of very low tumor content or when MLPA results are equivocal [124]. More 
recently,  Moelans  et  al.  evaluated  the  usefulness  of  MLPA  assay  for  the  simultaneous  testing  of  
HER-2/neu and TopoII alpha gene amplification status in 353 paraffin-embedded breast cancer samples, 
since  TopoII  amplification  status  determines  the  anthracycline  sensitivity,  showing  TopoII  alpha 
amplification in 9% and HER2 in 13% of patients, respectively. The authors concluded that MLPA is 
an easy and accurate method to simultaneously detect breast cancer HER-2/neu and TopoII alpha copy 
number  status  in  paraffin-embedded  tissue,  and  thus  an  attractive  supplement  or  alternative  to 
CISH [125]. Taken together, all these reports clearly demonstrate that MLPA assay can be considered 
a powerful tool in the molecular analysis of different neoplasm. 
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3.5. MLPA and DNA Methylation 
A different application of MLPA analysis is one aimed at the identification of epigenetic alterations, 
that is modification in the pattern of DNA methylation of specific genes. DNA methylation within the 
CpG islands in the promoter region is associated with transcriptional silencing and is involved in 
several cellular processes, such as genomic imprinting, X chromosome inactivation, DNA repair, and 
others. An aberrant DNA methylation of imprinted genes is associated with several inherited human 
diseases,  and  somatic  “de  novo”  methylation  of  CpG  islands  in  tumor  suppressor  genes  has  been 
implicated in tumorigenesis [126,127]. The Methylation Specific MLPA (MS-MLPA) assay has been 
developed  in  order  to  detect  epigenetic  alterations  in  the  genes  involved  in  the  above  described 
disorders [128]. In the MS-MLPA assay the sequence targeted by specific probes contains a restriction 
site  for  the  HhaI  endonuclease,  able  to  recognize  the  unmethylated  GCGC  sequence.  After  the 
hybridization step, the annealed probe mix is treated with HhaI which digests probes hybridized to 
unmethylated  DNA  while  leaving  undigested  the  probes  hybridized  to  methylated  DNA.  As  a 
consequence, only these latter probes will be amplified by the PCR reaction. The comparison of the 
peak size of the methylation specific probes, between a sample and a control, provide information 
about the levels of methylation of the specific DNA regions targeted by the probes. Due to this ability, 
MS-MLPA at present represents the gold standard for the molecular diagnosis of several diseases caused 
by abnormal DNA methylation. One of the most widely used applications of MS-MLPA is related to the 
molecular diagnosis of Prader Willi syndrome (PWS) and Angelman syndrome, which are the most 
common genetic diseases due to alterations of genomic imprinting. Both diseases are linked to the 
chromosomal region 15q11-q13, with involvement of the paternal allele in PWS and the maternal 
allele  in  AS,  respectively.  PWS,  affecting  1:15000  live  births,  is  characterized  by  hypotonia, 
hypogonadism,  mental  retardation  and  feeding  difficulties  in  early  infancy,  followed  by  excessive 
eating in later infancy or early childhood. PWS can be caused by three different mechanism, namely  
(i) deletion of the paternal allele in the chromosomal region 15q11-q13 (70% of cases); (ii) maternal 
uniparental  disomy  (UPD)  for  the  chromosome  15  (25%  of  cases);  and  (iii)  abnormalities  in  the 
imprinting center sequence on 15q11-q13 (5% of cases) [129]. 
AS  is  a  neurogenic  disorder  characterized  by  mental  retardation,  microcephaly,  inappropriate 
laughter and seizures. AS is caused by a loss of function of the UBE3A gene in the same chromosomal 
region involved in the PWS, 15q11-13. The UBE3A deficit is due to deletion of the maternal allele in 
the chromosomal region 15q11-q13 (70% of cases), the presence of a sequence variant in UBE3A 
(11% of cases), paternal UPD (7% of cases) and variants in imprinting center sequence (3%). A single  
MS-MLPA probe set is used for the analysis of both diseases, being able to detect all the different 
alterations of the 15q11-q13 region, which in the past had to be analyzed using different techniques 
(Southern  Blot  or  FISH  for  deletion,  microsatellite  analysis  for  uniparental  disomy,  methylation 
analysis  for  the  alterations  in  the  imprinting  center  sequence).  Several  groups  have  reported  their 
experience with MS-MLPA in the study of PWS, evidencing the usefulness of this technique which 
resulted in accurate, reliable results, less time consuming compared to other methods, with the only 
limitation being the inability to differentiate between UPD and imprinting defects [130–133]. MS-MLPA 
has been successfully used also in the molecular diagnosis of other diseases related to genomic imprint 
alterations such as Beckwith-Wiedemann syndrome and Silver Russel syndrome [134–137]. Int. J. Mol. Sci. 2012, 13  3260 
 
 
The second important field of application of the MS-MLPA assay is the one related to the analysis 
of methylation-specific inactivation of tumor suppressor genes in cancer. MS-MLPA has been used to 
analyze promoter hypermethylation of specific genes such as MGMT, TIMP3 and CDKN2A in different 
tumors  [112,138–142].  Moreover,  the  MS-MLPA  assay  has  been  used  to  simultaneously  detect  the 
methylation levels of up to 25 cancer-related genes, evidencing frequent promoter hypermethylation of 
specific genes in different cancers and demonstrating the association between epigenetic modifications, 
progression  of  the  disease  and  response  to  therapy  [103,143–160].  More  recently,  the  MS-MLPA 
approach has been used to evidence alterations in the methylation status of microRNA-associated CpG 
Islands  in  a  large  series  of  hereditary  and  sporadic  carcinomas  [161].  All  these  studies  strongly 
demonstrated  that  MS-MLPA  is  a  powerful  tool  to  analyze  epigenetic  alterations  in  cancer  for 
diagnostic as well as therapeutic purposes, also when one considers the ability of this approach to work 
on archival formalin-fixed, paraffin-embedded samples as well. 
Although  MRC-Holland  offers  an  ever-growing  range  of  MLPA  probemixes,  the  application  of 
interest may be too rare or not yet sufficiently investigated to warrant the development of a new SALSA 
MLPA probemix or to add other probes to MLPA probemix. In both cases, it is possible to develop a 
synthetic  probe  set  for  screening  a  specific  region.  This  represents  an  efficient,  rapid  and  robust 
alternative  for  research  (and  potentially  diagnostic)  deletion  and  duplication  screening  of  multiple 
genomic loci [162]. 
3.6. Limits of the MLPA Assay 
MLPA offers a rapid means of scanning up to 40 loci for gene dosage, and is likely to be widely 
used in research and diagnostic settings. However, there are still some limitations. Although MLPA is 
reported to work with only 20 ng and the results not to be related to the amount of used sample DNA, 
in our experience we have found that 100–200 ng are required for reliable and reproducible results and 
that MLPA is also sensitive to the kind of sample used for DNA extraction (e.g., blood or buccal swab). 
Thus, it is recommended to compare different MLPA analyses only by using DNA extracted from the 
same tissue with the same method. MLPA reactions are more sensitive to contaminants (e.g., PCR 
inhibitors such as small remnants of phenol) and DNA degradation than conventional PCR. 
As described above a crucial point in the interpretation of MLPA results is represented by the 
detection of deletions involving a single exon. In these cases, in fact, the apparent deletion could 
actually consist of a change in the exon sequence hampering the correct hybridization of the specific 
probe.  This  sequence  variation  can  be  represented  either  by  a  pathogenic  point  mutation  or  by  a 
polymorphism not affecting gene function. Thus, apparent single exon deletions detected by MLPA 
should be checked by an independent method. However, some probe sets contain probes able to evidence 
specific  point  mutations  in  the  gene  or  for  the  region  of  interest.  In  this  case,  MLPA  is  able  to 
discriminate known point mutations, as probes can be designed so that the ligation site is located directly 
at the site of the point mutation. Ligation will then only occur on non-mutated sequences, resulting in a 
decreased fluorescent signal in the case of mutated DNA. By adding common point-mutation-specific 
(PMS)-MLPA probes to dosage MLPA multiplexes, full dosage analysis and limited point mutation 
analysis can be performed simultaneously without any significant increase in labor [163]. Int. J. Mol. Sci. 2012, 13  3261 
 
 
As compared to FISH, MLPA cannot yet be used to investigate single cells. MLPA analysis of 
DNA samples from cell mixtures will give the average copy number per cell. In the case of tumor 
analysis, it is difficult to detect deletions of a certain gene if the sample from which the DNA was 
derived contained less than 50% cancer cells. The presence of mosaicism might go undetected by the test 
as the presence of normal cells can mask the presence of abnormal cells. 
MLPA is also unable to detect balanced rearrangements, since this technique relies on comparing 
quantities of DNA from a patient against a control, and balanced rearrangements produce a change in 
the order of DNA sequences, but not in the DNA quantity. 
MLPA  analysis  of  some  probe  sets  results  in  difficult  interpretation  due  to  the  presence  of 
unreliable  probes.  This  can  represent  a  limit  in  diagnostic  analysis.  Moreover,  it  is  necessary  to 
consider since the MLPA signal is affected by probe size and can have inter-individual variations; 
different data analysis can potentially lead to different results and interpretations. However, this problem 
can be resolved using in the analysis at least five control samples to compare to pathological ones. It is 
also recommended that the standard deviation of each probe of the control sample be analyzed to be 
sure that it is not significant (Tables 1 and 2). Int. J. Mol. Sci. 2012, 13  3262 
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Table 2. MLPA applications as diagnostic and discovery tool.  
Disease  Gene  Application  MLPA Advantages 
Proportion of Cases 
Due to del/dupl 
MLPA 
Detection Rate 
of del/dupl 
References 
DMD/BMD  DMD gene   Diagnosis  All the 79 exons of the DMD-gene analyzed in 
two reactions.  
Detection of duplications and heterozygous 
deletions. 
60–70% del 
5–10% dupl 
>99%  [25,29–37] 
SMA 
SMN1-SMN2  Diagnosis  Detection of heterozygous SMN1 loss.  
Ability to discriminate between SMN1 deletions 
and conversions to SMN2. 
95%  >98%  [46–51] 
CMT/HNPP 
PMP22  Diagnosis  All the PMP22 exons analyzed in a single 
reaction. A single probe set able to analyze two 
different conditions. 
Dupl 70%–80% CMT. 
Deletion 85% of 
HNPP cases 
>95%  [57–59] 
LWD 
SHOX  Diagnosis/Research  Ability to analyze both the SHOX gene coding 
region and the enhancer region.  
Detection of partial gene deletions and 
duplications. 
40% del  >80%  [68–72] 
Aneuplodies of 
13, 18, 21, X and 
Y chromosomes 
- 
 
Diagnosis  A single probe mix for the detection of several 
aneuploidies.  
-  >95%  [73–76] 
BC, OC   BRCA1, BRCA2  Diagnosis/Research  Detection of large gene rearrangements.  15–30%  NA  [79–84] 
FAP  APC  Diagnosis/Research  Detection of large gene rearrangements.   15–25%  NA  [85–89] 
HNPCC  MLH1, MSH2  Diagnosis/Research  A single probe set for all exons of both genes  MLH1:5% 
MSH2: 20% 
NA  [90–95] 
PWS/AS  15q11-q13 region  Diagnosis  A single MS-MLPA probe set used for the 
analysis of both diseases. 
Methylation 
abnormality 95% 
99%  [130–133] 
Del = deletions; dupl = duplications; NA = not available; DMD = Duchenne Muscular Dystrophy; BMD = Becker Muscular Dystrophy; SMA = Spinal Muscular Atrophy; 
CMT = Charcot Marie Thoot; HNPP = Hereditary Neuropathy with liability to Pressure Palsies; LWD = Leri Weill Dyschondrosteosis; BC/OC = Breast/Ovarian cancer; 
FAP = Familial adenomatous polyposis; HNPCC = Hereditary nonpolyposis colorectal cancer; PWS/AS= Prader Willi/Angelman Syndrome Int. J. Mol. Sci. 2012, 13 
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4. Conclusions 
In only  a few  years MLPA assay has become one of the most widely  used techniques for the 
molecular investigation of genetic diseases. The large application of this approach is the result of a 
number of advantages provided by MLPA assay when compared to other techniques. In fact, MLPA 
analysis is a high throughput analysis, allowing up to 96 samples to be handled simultaneously, with 
results being available within 24 h. Moreover, MLPA is a multiplex technique, allowing the study of 
several  regions  of  the  human  genome  in  a  single  reaction.  Target  sequences  are  very  short  (50–70 
nucleotides), allowing MLPA to identify single gene aberrations, too small to be detected by FISH. The 
MLPA reaction can also be carried out on DNA extracted from a buccal swab, providing an easier 
system of sample collection compared to peripheral blood withdrawal. Finally, compared to array CGH, 
MLPA is a low cost and technically uncomplicated method. Over 300 probe sets are so far commercially 
available, dedicated to the study of several human diseases. In this review we have analyzed some of the 
most common applications of the MLPA assay, but this technique has also demonstrated its usefulness in 
the study of several other diseases such as Rett Syndrome, α-thalassemia, disorders of sex development, 
congenital adrenal hyperplasia, idiopathic mental retardation and Parkinson’s disease [164–171]. Due to 
this wide range of diseases, it is very likely that MLPA analysis will represent in the near future a basic 
technique for the molecular analysis of genetic disorders, used in all laboratories performing diagnostic 
genetic testing both as a confirmation tool and as a diagnostic system applicable also to the copy 
number variation analysis in rare genetic conditions. Moreover in the future MLPA could be applied to 
large  CNV  screening,  since  recent  reports  have  highlighted  the  possibility  that  gene  copy  number 
variations may play a role in the development of complex disorders and suggested that some of these 
variations may be very common. 
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